Application of propionibacterium acnes in preparation of medicine for preventing and / or treating skin injury

Abstract

The invention discloses application of propionibacterium acnes in preparation of a medicine for preventing and / or treating skin injury. Experiments prove that the propionibacterium acnes can prevent and relieve ultraviolet skin injury by adjusting local microecology of skin, reducing ultraviolet-induced DNA injury, inhibiting inflammatory factor expression and lipid oxidation and the like, and can achieve a natural intervention effect with low side effect and high specificity; therefore, the compound has potential to be used as a medicine for preventing and / or treating ultraviolet skin injury.

Description

Technical Field

[0001] This invention relates to the field of skin injury drug technology, and in particular to the use of Propionibacterium acnes in the preparation of drugs for the prevention and / or treatment of skin injuries. Background Technology

[0002] Photodermatitis, also known as phototoxic dermatitis or ultraviolet dermatitis, is an acute inflammatory reaction caused by excessive exposure of the skin to sunlight, especially UVB ultraviolet radiation. Clinical manifestations include erythema, edema, peeling, itching, and even blisters, severely impacting patients' quality of life. In high-altitude areas, due to higher ultraviolet radiation intensity and dry air, the incidence of photodermatitis in the local population is significantly higher, making prevention and treatment urgently needed.

[0003] Current treatment methods include traditional methods such as oral nonsteroidal anti-inflammatory drugs (such as indomethacin, ibuprofen, etc.) and topical corticosteroids (such as hydrocortisone ointment, mometasone furoate, etc.); as well as adjunctive treatments such as local cold compresses and topical moisturizing and repairing agents (such as topical preparations made from natural plant extracts (such as aloe vera, centella asiatica, etc.)) to reduce redness and swelling of the skin after sun exposure.

[0004] However, traditional treatment methods have the following drawbacks: (1) poor specificity: although they can relieve symptoms in the short term, they cannot provide therapeutic interventions targeting the UVB damage mechanism; (2) many side effects: long-term use of topical hormones can lead to side effects such as skin atrophy and pigmentation. Topical hormones also have problems such as drug resistance and easy recurrence, and are especially unsuitable for long-term use by people living in high-altitude areas. Both traditional treatment methods and adjuvant treatments focus on relieving symptoms rather than treating photodermatitis from the perspective of pathogenesis.

[0005] Therefore, there is a need to develop drugs to prevent and treat UV-induced skin damage. Summary of the Invention

[0006] The purpose of this invention is to address the technical deficiencies in the prior art. In a first aspect, it provides the use of Propionibacterium acnes in the preparation of drugs for the prevention and / or treatment of skin damage.

[0007] The skin damage was caused by ultraviolet radiation (especially UVB).

[0008] The skin lesion described is photodermatitis.

[0009] The viable bacterial concentration of Propionibacterium acnes in the drug, expressed as colony count, is 5.96 × 10⁻⁶. 6 -1.78×10 9 CFU / ml.

[0010] The viable bacterial concentration of Propionibacterium acnes in the drug, expressed as colony count, is 7.50 × 10⁻⁶. 6 -5.62×10 8 CFU / ml.

[0011] The viable concentration of Propionibacterium acnes in the drug, expressed as colony count, is 1.00 × 10⁻⁶. 7 -3.16×10 8 CFU / ml.

[0012] The drug is a topical skin preparation, including but not limited to solutions, creams, ointments, gels, sprays, and patches.

[0013] In a second aspect, the present invention provides a composition comprising Propionibacterium acnes and a pharmaceutically acceptable carrier.

[0014] The carrier is a product that provides the carbon source, nitrogen source, vitamins, short peptides, amino acids and other substances needed for the growth and reproduction of Propionibacterium acnes.

[0015] Thirdly, the present invention provides the use of the above composition in the preparation of medicaments for the prevention and / or treatment of skin injuries, wherein the skin injuries are preferably caused by ultraviolet radiation (especially UVB band ultraviolet radiation).

[0016] This invention addresses the challenge of treating the high incidence of photodermatitis in high-altitude, sun-exposed environments by providing a highly specific and low-side-effect therapeutic drug—Propionibacterium acnes (CA). Through research on high-altitude populations, this invention discovered that some bacterial species may possess natural protective functions in skin protection. Further, based on the characteristics of the flora in high-altitude populations, a differential bacterial species functional screening study identified Propionibacterium acnes, a type of dermal commensal bacteria. Animal experiments demonstrated that CA can regulate innate immunity by modulating the local skin microecology, reducing UV-induced DNA damage, inhibiting inflammatory factor expression, and lipid oxidation, thereby preventing and alleviating UV-induced skin damage. It also possesses the advantages of low side effects and high specificity, making it a potential drug for the prevention and / or treatment of UV-induced skin damage. Attached Figure Description

[0017] Figure 1 The diagram shown is a flowchart of the experiment.

[0018] Figure 2 The image shown is a photograph of skin lesions in a mouse.

[0019] Figure 3 The image shown is an H&E staining image of mouse skin tissue.

[0020] Figure 4 The image shown is a bar chart of mouse skin epidermal thickness.

[0021] Figure 5 The image shown is a Sirius red staining image of mouse skin tissue.

[0022] Figure 6 The image shows a bar chart illustrating the percentage of mature type I collagen fibers in mouse skin tissue.

[0023] Figure 7 The image shown is an immunohistochemical staining image of CPD in mouse skin tissue.

[0024] Figure 8 The image shows a bar chart of MDA content in mouse skin tissue.

[0025] Figure 9 The image shows a bar chart of the expression of inflammatory factors and chemokines in mouse skin tissue.

[0026] Figure 10 The figure shown illustrates the difference in relative abundance of CA bacteria between the group without skin damage and the group with skin damage.

[0027] Figure 11 The figure shown is a graph of significantly different bacterial species obtained from linear discriminant analysis (LDA) between the group with no skin damage and the group with skin damage.

[0028] Figure 12 The diagram shows the Simpson index of the gut microbiota between the group with no skin damage and the group with skin damage.

[0029] Figure 13 The image shows a bar chart illustrating the percentage of CPD-positive areas in mouse skin tissue. Detailed Implementation

[0030] With the development of research on skin microecology, the role of skin symbiotic bacteria (such as Staphylococcus epidermidis and Propionibacterium) in maintaining skin microecology and regulating immune responses has gradually attracted attention. For example, patent document CN102975707A discloses a topical composition using probiotics (such as Lactobacillus) that can be used to regulate skin microecology and reduce acne, eczema, etc.

[0031] After conducting research on patients with photodermatitis, particularly those from high-altitude areas, the applicant discovered that certain bacterial species may have natural protective effects on the skin. Based on the enrichment characteristics of the bacterial flora in high-altitude populations, the applicant guided specific application strategies for skin disease intervention. Ultimately, through differential bacterial species function screening, the applicant found that fully utilizing skin symbiotic bacteria, especially *Propionibacterium acnes*, as natural symbiotic bacteria or biological protective factors can regulate the skin's natural immune system, thereby treating UV-induced skin damage from the perspective of regulating the skin's microecological mechanisms. The applicant further validated through animal experiments that exogenous colonization of *Propionibacterium acnes* can prevent or alleviate UV-induced skin damage, and optimized the dosage based on the relationship between dose gradients and prevention and treatment effects. This suggests the potential application of *Propionibacterium acnes* in the prevention and treatment of UVB-induced photodermatitis (e.g., in high-altitude environments).

[0032] Propionibacterium acnes is a Gram-positive anaerobic bacillus belonging to the phylum Actinobacteria and the genus Propionibacterium. It is a short rod-shaped bacterium, approximately 0.5–1.5 μm in size, usually occurring singly or in pairs. It lacks flagella and is non-motile. It is anaerobic and can grow in lipid-rich environments, commonly found in the pilosebaceous unit, especially abundantly on the skin after puberty. Metabolites of Propionibacterium acnes (such as lipases) can break down sebum, producing free fatty acids and triggering folliculitis. It is widely considered one of the main pathogens causing acne.

[0033] The following specific embodiments illustrate the content of the present invention in more detail and further elaborate the present invention, but these embodiments are by no means intended to limit the present invention.

[0034] Example 1: Screening of Propionibacterium acnes (CA) in a high-altitude population. This invention focuses on individuals living in high-altitude regions. Several volunteers were recruited and divided into a "no-skin-damage group" and a "skin-damage group" based on the presence or absence of UV-induced skin damage (such as photodermatitis). Microbial samples were collected from specific areas of the volunteers' faces (e.g., forehead, nose wings). Metagenomic analysis of the skin microbiota was performed using 16S rRNA high-throughput sequencing, and the raw data underwent quality control and cluster analysis. Relative abundance calculations revealed a significantly increased relative abundance of *Propionibacterium acnes* in the no-skin-damage group, marking the first discovery of significant enrichment of *Propionibacterium acnes* in a high-altitude, no-skin-damage population.

[0035] This invention verifies the relationship between skin microbiome structure and skin damage by performing 16S sequencing analysis on the skin microbiome of volunteers in the groups with no skin damage and those with skin damage, combined with microbiome abundance and diversity indices. Figure 10 The relative abundance distribution of CA bacteria in two groups of skin samples is shown. Figure 10 The results showed that CA was dominant in the group without skin damage, while its abundance decreased in the group with skin damage, suggesting that CA is related to skin health. Figure 11 The results of differentially significant bacterial species obtained based on linear discriminant analysis (LDA) showed that CA was enriched in the group without skin lesions, while other bacterial species were significantly enriched in the group with skin lesions, indicating that CA contributed significantly to the differences in community structure between the two groups. Further analysis using the Simpson diversity index (see...) Figure 12 The Simpson index reflects community diversity and evenness. The results showed that the Simpson index was significantly higher in the skin lesion group, indicating a decrease in the proportion of dominant symbiotic bacteria (CA) in the skin lesion group. This led to increased community evenness, i.e., a higher Simpson index, suggesting disturbance of the skin microecology. Based on these results, this invention proposes a novel approach of "natural symbiotic bacteria intervention in skin lesions," providing a new intervention strategy for skin lesions such as photodermatitis.

[0036] Example 2: Preparation of CA bacterial preparation The *Propionibacterium acnes* (strain number: BNCC-330605) used in this embodiment was purchased from the BeiNa Biotechnology Research Institute and was a lyophilized strain preserved in a frozen state. Before the experiment, the strain was first revived and cultured on Columbia blood agar plates. The operation steps are as follows: Take out the lyophilized strain, add sterile physiological saline to slowly dissolve and mix thoroughly, and inoculate it onto a pre-prepared Columbia blood agar plate (containing 5% defibrinated sheep blood, Columbia Blood Agar, purchased from Guangdong Huankai Microbial Technology Co., Ltd., CP0910 Columbia CNA blood agar plate), and incubate in an anaerobic incubator at 37°C for 48 hours until colonies have grown significantly. Then, use a sterile inoculation loop to pick a single typical colony from the Columbia blood agar plate and inoculate it into 10 mL of nutrient broth (Nutrient Broth medium, purchased from Guangdong Huankai Microbial Technology Co., Ltd., 022011 nutrient broth medium), and continue to incubate in an anaerobic environment at 37°C until the optical density (OD) of the bacterial solution is reached. 600 The colony count (measured using a Biotck-Cytation 5 microplate reader) reached 0.6, indicating that the bacterial culture had entered the logarithmic growth phase. To prepare bacterial cultures of different concentrations, the original bacterial culture was diluted with PBS at a volume ratio, yielding colony counts of 1.30 × 10⁶. 7 CFU / mL, 3.16×10 7 CFU / mL, 1.78×10 8 CFU / mL bacterial suspensions were used as low, medium, and high dose groups for subsequent experiments.

[0037] Experimental Example 1: Establishment of a UVB-induced skin damage model The bacterial suspensions prepared in Example 2 at low, medium, and high doses were used in an animal model of UVB-induced skin damage. The establishment of the UVB-induced skin damage model included the following steps: 6-8 week old Babl-c mice (purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd.) were acclimatized for three days, their backs were prepared, and they were placed in a UV irradiation box with their vertical movement restricted by wire mesh. Irradiation was performed using a TL 20W / 12RS fluorescent lamp (Philips, Eindhoven, Holland), with the light source 33 cm away from the mice, and the UV lamp irradiation intensity was 700 μW / cm². 2 The irradiation time was approximately 35 minutes, with a cumulative single irradiation dose of 1500 mJ / cm². 2 Intervention was administered immediately after one irradiation session. The control group (PBS), model group (PBS + irradiation), and treatment groups (low, medium, and high doses of bacterial suspension + irradiation) received 100 μL / day / time, applied evenly to the back skin using a cotton swab. (See flowchart). Figure 1 After 6 consecutive days of administration, the skin damage on the backs of mice was observed, and the results are shown in the table below. Figure 2 Then, using surgical instruments, a 1.5cm incision is quickly made in the prepared irradiation area on ice. Skin tissue in a 1.5cm area, for later use.

[0038] Figure 2 The results showed that after UVB irradiation, mice developed obvious erythema on their backs, appearing as dark red or pink. The skin surface was slightly swollen and tight, accompanied by local roughness, and some areas showed slight desquamation or dryness. A few mice showed slight blisters or mild bleeding points, exhibiting typical photodamage morphology. After intervention with CA bacterial solution, the erythema on the backs of mice was significantly reduced, and the color returned to a light pink or pale red close to that before irradiation. The swelling and tightness of the skin were reduced, and the surface felt smooth and soft. The roughness and desquamation were significantly improved, and the skin texture returned to uniformity. Overall, the skin condition was close to that of the control group, indicating that CA bacterial solution intervention has an ameliorative effect on UVB-induced skin inflammation and skin damage.

[0039] Experiment Example 2: H&E Staining Experiment Specifically, skin tissue obtained from Example 1 was fixed in 4% formaldehyde for 24 hours, then routinely embedded in paraffin and sectioned (approximately 5 μm thick). The tissue was then subjected to the following steps: dewaxing with xylene, hydration, hematoxylin staining (5 min), differentiation with hydrochloric acid and alcohol, bluing, washing, eosin staining (3 min), dehydration, clearing, and mounting with neutral resin. After staining, observation and image acquisition were performed using an optical microscope (Nikon Eclipse E200, Nikon, Japan). The results are shown in [Figure number missing]. Figure 3 It is used to assess changes in skin structure.

[0040] Figure 3 HE staining results showed that the epidermis of the back skin of mice in the blank group was of uniform thickness, with a dense and intact stratum corneum, uniform staining of keratinocyte nuclei, and normal structure of hair follicles and sebaceous glands, with no obvious pathological changes. In the model group, the epidermis was significantly thickened (see arrows in the figure), the stratum corneum was thickened and loosely arranged, with localized stratum corneum peeling; the keratinocyte nuclei showed uneven staining depth and slightly irregular morphology; atrophy and structural disorder were observed in hair follicles and sebaceous glands. After intervention with CA bacterial solution, the epidermal thickness of the back skin of mice was significantly restored, the stratum corneum was densely arranged, the uniformity of nuclear staining was improved, and the structure of hair follicles and sebaceous glands was restored to a more regular shape than in the model group. The overall tissue morphology was close to that of the blank group, indicating that bacterial solution intervention has a repairing effect on UVB-induced skin structural abnormalities.

[0041] right Figure 3 The results are quantified to obtain, for example Figure 4 The results show the quantitative results of the epidermal thickness of the mouse back skin. Figure 4 The results showed that the epidermal thickness in the model group was significantly increased, with a statistically significant difference compared to the control group (P < 0.05), indicating that UVB irradiation caused significant epidermal proliferative damage. After intervention with CA bacterial solution, the epidermal thickness recovered to near the level of the control group, and there was no significant difference compared to the control group (P > 0.05), indicating that the CA bacterial solution has a significant repair effect on UVB-induced epidermal thickening and suggests that it has a potential protective effect in maintaining the integrity of skin structure.

[0042] Experiment Example 3: Sirius Red Staining Experiment Experiment Example 3: Sirius Red Staining Experiment Mouse skin tissue obtained from Example 1 was fixed in 4% formaldehyde for 24 h, then routinely embedded in paraffin and sectioned (approximately 5 μm thick). After dewaxing and hydration, the sections were stained with 0.1% Sirius red solution (containing saturated picric acid) for 60 min, dehydrated with anhydrous ethanol, cleared with xylene, and mounted. The stained sections were observed under a polarized light microscope (Olympus BX53-P, Olympus, Japan) to assess the repair of dermal damage induced by UVB. The results are shown in [Figure 1]. Figure 5 The red or orange-red birefringent signal represents mature type I collagen fibers, while the yellow or yellow-green signal represents fine or newly formed type III collagen fibers.

[0043] Figure 5 The results showed that the dermis of mice in the blank control group was dominated by red collagen fiber signals with intact structure; in the model group, the red collagen fiber signal was significantly reduced, while the yellow signal increased and was disordered, indicating that mature collagen fibers had degraded. After application of high, medium, and low doses of Propionibacterium acnes (CA) bacterial solution, the red collagen fiber signal was significantly restored, and the collagen fiber arrangement became more regular.

[0044] right Figure 5 Quantitatively obtained from the red collagen fiber region Figure 6 The results are shown. Figure 6 The results showed that the proportion of mature collagen fibers in the model group was significantly reduced, while after topical administration of CA, this indicator was significantly higher in all treatment groups than in the model group. These results indicate that topical administration of Propionibacterium acnes can effectively reduce UVB-induced dermal collagen damage, promote skin structure repair, and make it indistinguishable from unexposed normal skin.

[0045] The results of Experiments 1 through 3 all demonstrate that topical administration of Propionibacterium acnes can significantly reduce UVB-induced skin damage, suggesting that it may be a potential treatment for UV-induced skin damage.

[0046] Experiment Example 4: CPD Immunohistochemical Staining (Cyclobutane Pyrimidine Dimer IHC) Experiment CPD (cyclobutane pyrimidine dimer) is commonly used in immunohistochemical assays to verify DNA damage induced by ultraviolet (UV) radiation. Its principle and relationship are as follows: When skin tissue is exposed to UVB (280–320 nm), adjacent pyrimidine bases (mainly thymine) on the DNA strand undergo covalent cross-linking, forming a cyclobutane pyrimidine dimer. This chemical cross-linking distorts the DNA double helix structure, hindering the normal replication and repair of DNA polymerase. CPD is the most significant direct DNA damage product of UVB, and as a marker of DNA damage, its content and distribution can quantitatively or semi-quantitatively reflect the degree of DNA damage caused by UVB irradiation.

[0047] Specifically, skin tissue obtained from Example 1 was fixed in 4% formaldehyde for 24 hours, then routinely embedded in paraffin and sectioned (approximately 5 μm thick). After dewaxing and hydration, the paraffin sections underwent antigen (CPD) retrieval (citric acid buffer, pH 6.0, heat retrieval at 95°C for 10 min). The sections were then incubated with blocking buffer (TBST solution containing 5% skim milk powder) for 2 hours, followed by incubation at 4°C overnight with CPD primary antibody (KAMIYA's KBC-MC-062, diluted 1:100 with TBST solution containing 5% skim milk powder). The next day, the sections were incubated with HRP-labeled secondary antibody (ZSGB-BIO, China), followed by DAB staining, hematoxylin counterstaining, dehydration, and mounting. The expression levels of DNA-damaged positive cells in the skin were observed using an optical microscope (Nikon Eclipse Ci). The results are shown in [Figure number missing]. Figure 7 .

[0048] Depend on Figure 7 It is evident that UVB leads to an increase in CPD in the epidermis and dermis (see circled area in the figure), while topical application of different concentrations of Propionibacterium acnes solution can inhibit the increase in CPD.

[0049] right Figure 7 The results are quantified to obtain, for example Figure 13 The results are shown. Figure 13 Compared with the control group and the drug-treated group, the CPD-positive area in the model group was significantly increased, while there was no significant difference in the CPD-positive area between the drug-treated group and the control group after applying bacterial solution. This indicates that CA can reduce photomutation by inhibiting CPD expression and has the effect of resisting DNA damage.

[0050] Experiment Example 5: Inflammatory Cytokine Multiplex Assay Experiment Specifically, a portion of skin tissue taken from Experiment 1 was homogenized, centrifuged, and the supernatant was collected. Then, using the Luminex Multifactor Liquid Chromatography-Analog System (Luminex MAGPIX, USA), the levels of inflammatory factors such as IL-2, IL-17A, IFN-γ, and IL-1β in the supernatant were detected using a commercially available multifactor detection kit (Bio-Rad Bio-Plex Pro™ Mouse Cytokine Panel). The results are shown below. Figure 9 This reflects the level of inflammatory response.

[0051] The results showed that after ultraviolet irradiation, the levels of inflammatory factors (IL-2, IL-17A, IFN-γ, IL-1β) and chemokines (CXCL1, CCL2, CCL3, CCL4) in mouse skin tissue were significantly increased. However, after bacterial treatment, the levels of these inflammatory factors and chemokines were significantly reduced, indicating that CA can inhibit the inflammatory response in the skin after ultraviolet irradiation.

[0052] Experiment Example 6: MDA Level Detection (Malondialdehyde Assay) Specifically, the skin tissue obtained in Example 1 was homogenized and then analyzed using an MDA detection kit (Nanjing Jiancheng Bioengineering Institute, A003-1) according to the manufacturer's instructions. The principle is based on the reaction of MDA with thiobarbituric acid (TBA) to form a red complex. The reaction system was heated in a water bath (95℃, 40 min) and then cooled in an ice bath. The supernatant was collected by centrifugation at 4,000 rpm, and the absorbance was read at 532 nm using a UV spectrophotometer (Thermo Fisher Scientific, GENESYS 50). The MDA content per unit protein was calculated, and the results are shown in [Figure number missing]. Figure 8 To assess the level of lipid peroxidation damage.

[0053] These results indicate that UVB irradiation also significantly increases the level of MDA, the end product of lipid peroxidation, and that Propionibacterium acnes can alleviate lipid peroxidation levels, suggesting that CA has antioxidant effects.

[0054] Example 3: Topical live bacteria preparation with Propionibacterium acnes as the active ingredient Topical composition with Propionibacterium acnes as the main active ingredient It includes at least: bacterial culture, carrier (a product that can provide the carbon source, nitrogen source, vitamins, short peptides, amino acids and other substances required for bacterial growth and reproduction, such as culture medium (which can be peptone), including but not limited to liquid culture medium, solid culture medium, etc.), and physiological saline system; Viable bacteria concentration range: 5.96 × 10⁻⁶ 6-1.78×10 9 CFU / ml; It can be prepared as solutions, creams, gels, patches, etc.

[0055] This topical composition can be used to treat UV-induced skin damage by applying it topically, and can be applied to scenarios such as fieldwork, sun protection and skin care, and medical repair.

[0056] This invention is the first to apply CA strain externally to mouse skin and demonstrates in a mouse model of UVB-induced skin damage that CA strain can reduce skin tissue damage, inhibit inflammatory response, reduce DNA damage levels, and has antioxidant effects.

[0057] Compared with existing technologies, this invention utilizes the natural symbiotic bacterium CA to intervene in UVB-induced skin damage, offering advantages such as being natural, safe, and microecologically friendly. Its intervention primarily targets epidermal thickening, stratum corneum disorder, and follicle / sebaceous gland abnormalities caused by UVB photodamage. By restoring epidermal thickness, improving stratum corneum structure, regulating the local skin microecology, and inhibiting DNA damage and the release of inflammatory factors, it achieves precise repair of skin damage, exhibiting high specificity. This invention has verified this specific effect through experimental data including visual observation, HE staining, quantification of epidermal thickness, immunohistochemistry, detection of multiple inflammatory factors, and MDA detection.

[0058] Compared to existing treatments for photodermatitis (such as physical sunscreens, corticosteroids, and NSAIDs), this invention, for the first time, analyzes the differences in bacterial flora between healthy individuals and those with skin damage in high-altitude areas. It reveals that *Propionibacterium acnes* is significantly enriched in normal skin, suggesting its natural skin-protective function. Animal experiments further confirm its significant alleviating and repairing effects on UVB-induced skin damage. In animal models, topical application of different concentrations of *Propionibacterium acnes* bacterial solutions significantly reduced UVB-induced epidermal thickening and collagen fiber loss in mice, decreased the expression of the DNA photodamage product cyclobutanepyrimidine dimer (CPD), and downregulated MDA (malondialdehyde) levels, indicating a decrease in lipid peroxidation. Furthermore, this bacterium effectively inhibits the expression of inflammatory factors (such as IL-2, IL-17A, IFN-γ, and IL-1β), demonstrating a multi-dimensional effect of anti-inflammation, anti-oxidation, and tissue repair—advantages that are difficult to achieve simultaneously with traditional drugs or chemical sunscreens. This invention provides a novel prevention and treatment strategy that is more biocompatible, microecologically friendly, and safe by topical application of live and / or inactivated and / or attenuated Propionibacterium acnes (CA) preparations.

[0059] The above description is only a preferred embodiment of the present invention. It should be noted that, for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered as part of the present invention.

Claims

1. Use of P. acnes for the preparation of a medicament for the prevention and / or treatment of skin damage.

2. Use according to claim 1, characterized in that, The skin damage is caused by UV light, especially UVB.

3. Use according to claim 1 or 2, characterized in that, The skin damage is solar dermatitis.

4. Use according to any one of claims 1 to 3, characterized in that, The viable bacterial concentration of said P. acnes in said medicament is 5.96 x 10 6 -1.78 x 10 9 CFU / ml, as counted by colony forming units.

5. Use according to any one of claims 1 to 4, characterized in that, The viable bacterial concentration of said P. acnes in said medicament is 7.50 x 10 6 -5.62 x 10 8 CFU / ml, as counted by colony forming units.

6. Use according to any one of claims 1 to 5, characterized in that, The viable bacterial concentration of said P. acnes in said medicament is 1.00 x 10 7 -3.16 x 10 8 CFU / ml, as counted by colony forming units.

7. Use according to any one of claims 1 to 6, characterized in that, The medicament is a topical skin preparation, including but not limited to solutions, creams, ointments, gels, sprays, patches, etc.

8. A composition characterized in that, The composition comprises P. acnes and a pharmaceutically acceptable carrier.

9. The composition of claim 8, wherein, The carrier is a product that provides the carbon source, nitrogen source, vitamins, short peptides, amino acids, etc. required for the growth and reproduction of P. acnes.

10. Use of the composition of claim 8 or 9 for the preparation of a medicament for the prevention and / or treatment of skin damage, preferably caused by UV light, especially UVB.

Images